首页 >>2013年10期
人巨细胞病毒感染的危害及其疫苗研发进展
作者:刘晓林 王同展 王海岩 张文强 徐爱强
全文:PDF()

摘要:

关键词:

Abstract:

Key words:

发表日期:2013/10

引用本文:

图/表:

    暂无图表

参考文献:

[1]Craig JM, Macauley JC, Weller TH, et al. Isolation of intranuclear inclusion producing agents from infants with illnesses resembling cytomegalic inclusion disease. Proc Soc Exp Biol Med, 1957, 94(1): 412.
[2]Hill RB Jr, Rowlands DT Jr, Rifkind D. Infectious pulmonary disease in patients receiving immunosuppressive therapy for organ transplantation. N Engl J Med, 1964,271: 10211027.
[3]Balkhair AA, AlMuharrmi ZK, Ganguly S, et al. Spectrum of aids defining opportunistic infections in a series of 77 hospitalised HIVinfected Omani patients. Sultan Qaboos Univ Med J, 2012, 12(4):442448.
[4]Chen J, Hu L, Wu M, et al. Kinetics of IgG antibody to cytomegalovirus (CMV) after birth and seroprevalence of antiCMV IgG in Chinese children. Virol J, 2012, 9:304.
[5]Wong A, Tan KH, Tee CS, et al. Seroprevalence of cytomegalovirus, toxoplasma and parvovirus in pregnancy. Singapore Med J, 2000, 41(4):151155.
[6]Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol, 2010, 20(4): 202213.
[7]Cannon MJ, Hyde TB, Schmid DS. Review of cytomegalovirus shedding in bodily fluids and relevance to congenital cytomegalovirus infection. Rev Med Virol, 2011, 21(4):240255.
[8]Shen CY, Chang BL, Chang SF, et al. Molecular epidemiology of cytomegalovirus infection in kindergarten children. J Med Virol, 1996, 48(1):3337.
[9]GautheretDejean A, Aubin JT, Poirel L, et al. Detection of human betaherpesvirinae in saliva and urine from immunocompromised and immunocompetent subjects. J Clin Microbiol, 1997, 35(6):16001603.
[10]Clarke LM, Duerr A, Feldman J, et al. Factors associated with cytomegalovirus infection among human immunodeficiency virus type 1seronegative and seropositive women from an urban minority community. J Infect Dis, 1996, 173(1):7782.
[11]Stagno S, Pass RF, Dworsky ME, et al. Maternal cytomegalovirus infection and perinatal transmission. Clin Obstet Gynecol, 1982, 25(3):563576.
[12]Pass RF, Stagno S, Dworsky ME, et al. Excretion of cytomegalovirus in mothers: observations after delivery of congenitally infected and normal infants. J Infect Dis, 1982, 146(1):16.
[13]Schleiss MR. Role of breast milk in acquisition of cytomegalovirus infection: recent advances. Curr Opin Pediatr, 2006, 18(1):4852.
[14]Kenneson A, Cannon MJ. Review and metaanalysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol, 2007, 17(4): 253276.
[15]Enders G, Daiminger A, Bder U, et al. Intrauterine transmission and clinical outcome of 248 pregnancies with primary cytomegalovirus infection in relation to gestational age. J Clin Virol, 2011, 52(3):244246.
[16]Hamprecht K, Maschmann J, Vochem M, et al. Epidemiology of transmission of cytomegalovirus from mother to preterm infant by breastfeeding. Lancet, 2001, 357(9255): 513518.
[17]金奇. 医学病毒学. 北京: 科学出版社, 2001.
[18]Griffiths P, Plotkin S, Mocarski E, et al. Desirability and feasibility of a vaccine against cytomegalovirus. Vaccine, 2013, 31 Suppl 2: B197203.
[19]HalwachsBaumann G, Genser B, Danda M, et al. Screening and diagnosis of congenital cytomegalovirus infection: a 5y study. Scand J Infect Dis, 2000, 32(2): 137142.
[20]Boppana SB, Ross SA, Shimamura M, et al. Saliva polymerasechainreaction assay for cytomegalovirus screening in newborns. N Engl J Med, 2011, 364(22): 21112118.
[21]MussiPinhata MM, Yamamoto AY, Moura Brito RM, et al. Birth prevalence and natural history of congenital cytomegalovirus infection in a highly seroimmune population. Clin Infect Dis, 2009, 49(4): 522528.
[22]李登华, 马玉燕, 王磊一. 孕妇与胎儿巨细胞病毒感染的研究. 现代妇产科进展, 2001,10(5): 367369.
[23]沈敏勤. 江苏无锡市部分孕产妇和婴幼儿TORCH感染检测结果. 热带病与寄生虫学, 2012, 10(1): 4142.
[24]Boppana SB, Pass RF, Britt WJ, et al. Symptomatic congenital cytomegalovirus infection:neonatal morbidity and mortality. Pediatr Infect Dis J, 1992, 11(2):9399.
[25]Dollard SC, Grosse SD, Ross DS. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol, 2007, 17(5): 355363.
[26]Fowler KB, Stagno S, Pass RF. Maternal immunity and prevention of congenital cytomegalovirus infection. JAMA, 2003, 289(8): 10081011.  
[27]Grundy  JE, Lui SF, Super M, et al. Symptomatic cytomegalovirus infection in seropositive kidney recipients: reinfection with donor virus rather than reactivation of recipient virus. Lancet, 1988, 2(8603): 132135.
[28]Rubin RH. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. JAMA, 1989, 261(24): 36073609.
[29]Lowance D, Neumayer HH, Legendre CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med, 1999, 340(19): 14621470.
[30]Emery VC, HassanWalker AF, Burroughs AK, et al. Human cytomegalovirus (HCMV) replication dynamics in HCMVnaive and experienced immunocompromised hosts. J Infect Dis, 2002, 185(12): 17231728.
[31]Grob JP, Grundy JE, Prentice HG, et al. Immune donors can protect marrowtransplant recipients from severe cytomegalovirus infections. Lancet, 1987, 1(8536): 774776.
[32]Holbrook JT,Jabs DA,Weinberg DV, et al. Visual loss in patients with cytomegalovirus retinitis and acquired immunodeficiency syndrome before widespread availability of highly active antiretroviral therapy. Arch Ophthalmol, 2003, 121(1):99107.
[33]Brantsaeter AB,Liestl K,Goplen AK, et al. CMV disease in AIDS patients: incidence of CMV disease and relation to survival in a populationbased study from Oslo. Scand J Infect Dis, 2002, 34(1):5055.
[34]Erice A,Tierney C,Hirsch M, et al. Cytomegalovirus (CMV) and human immunodeficiency virus (HIV) burden, CMV endorgan disease, and survival in subjects with advanced HIV infection (AIDS Clinical Trials Group Protocol 360). Clin Infect Dis, 2003, 37(4):567578.
[35]Pawelec G, Derhovanessian E, Larbi A, et al. Cytomegalovirus and human immunosenescence. Rev Med Virol, 2009, 19(1): 4756.
[36]Looney RJ, Falsey A, Campbell D, et al. Role of cytomegalovirus in the T cell changes seen in elderly individuals. Clin Immunol, 1999, 90(2): 213219.
[37]Savva G, Pachnio A, Kaul B, et al. Cytomegalovirus infection is associated with increased mortality in the older population. Aging Cell, 2013, 12(3):381387.
[38]Arvin AM, Fast P, Myers M, et al. Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clin Infect Dis, 2004, 39(2): 233239.
[39]Plotkin SA, Starr SE, Friedman HM, et al. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial. Ann Intern Med, 1991, 114(7):525531.
[40]Pass RF, Zhang C, Evans A, et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med, 2009, 360(12): 11911199.
[41]Bernstein DI, Reap EA, Katen K, et al. Randomized, doubleblind, phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine, 2009, 28(2): 484493.
[42]KharfanDabaja MA, Boeckh M, Wilck MB, et al. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stemcell transplantation: a randomised, doubleblind, placebocontrolled, phase 2 trial. Lancet Infect Dis, 2012, 12(4):290299.
[43]Wilson SR, Wilson JH, Buonocore L, et al. Intranasal immunization with recombinant vesicular stomatitis virus expressing murine cytomegalovirus glycoprotein B induces humoral and cellular immunity. Comp Med, 2008, 58(2): 129139.
[44]Yue Y, Wang Z, Abel K, et al. Evaluation of recombinant modified vaccinia Ankara virusbased rhesus cytomegalovirus vaccines in rhesus macaques. Med Microbiol Immunol, 2008, 197(2): 117123.
[45]Zhong J, Rist M, Cooper L, et al. Induction of pluripotent protective immunity following immunisation with a chimeric vaccine against human cytomegalovirus. PLoS One, 2008, 3(9): e3256.
[46]CicinSain L, Bubic I, Schnee M, et al. Targeted deletion of regions rich in immuneevasive genes from the cytomegalovirus genome as a novel vaccine strategy. J Virol, 2007, 81(24): 1382513834.
[47]Griffiths PD. Burden of disease associated with human cytomegalovirus and prospects for elimination by universal immunisation. Lancet Infect Dis, 2012, 12(10):790798.

用户评论 0条

用户名: 密码: 登陆 注册
 
  • 9
  • 3
  •  4 : 页次:0/0页 共0条记录 5条/每页
    关于我们 | 专家风采 | 会员注册 | 继续教育
    地 址:北京市西城区东河沿街69号正弘大厦511室 邮 编:100052
    电话:010-51322302
    版权所有 中华医学会及中华预防医学杂志编辑部
    京ICP备 07035254 号